| 20090155827 | PIGF and FLT-1 as Prognostic Parameters for Cardiovascular Diseases - The present invention refers to a use of an ex vivo method comprising the determination of PlGF and sFlt-1 in a sample for diagnosis, risk stratification and/or monitoring of a vascular disease with atherosclerotic etiology, in particular a coronary heart disease such a unstable angina pectoris or myocardial infarction, and/or for estimation of the probability of developing such a disease, as well as for identification of a patient supposed to benefit from a therapy by agents reducing the risk for a cardiovascular disease. In the method (i) a ratio of [PlGF=high:sFlt-1=low], and/or (ii) a PlGF concentration in the upper two tertiles of a reference collective, and an sFlt-1 concentration in the lower tertile of the reference collective, and/or (iii) a PlGF result above a PlGF reference value, and an sFlt-1 result below an sFlt-1-reference value indicate an elevated probability for an adverse event. The present invention also refers to the used method. The present invention further refers to a diagnostic kit and its use as well as to an assay element and its use. | 06-18-2009 |
